LOC100041287 Inhibitors
LOC100041287 inhibitors act on upstream or downstream elements that modulate the protein's activity or expression. Inhibitors such as kinase inhibitors, PI3K inhibitors, and proteasome inhibitors, can influence the function of LOC100041287 by acting on kinases, phosphatidylinositol 3-kinases, and the ubiquitin-proteasome system, respectively. For example, kinase inhibitors like Staurosporine and Dasatinib obstruct the catalytic activity of kinases that may phosphorylate LOC100041287 or proteins interacting with it, thereby affecting its function. Similarly, PI3K inhibitors like LY294002 and Wortmannin disrupt PI3K-dependent signaling routes that could regulate LOC100041287's role in cellular processes such as growth, metabolism, and survival.
Proteasome inhibitors like Bortezomib alter protein degradation pathways that could dictate the stability and turnover of LOC100041287, affecting its cellular concentration and function. Other inhibitors like Rapamycin and Palbociclib target mTOR and cyclin-dependent kinases, respectively, which are central to processes like protein synthesis and cell cycle progression. By interfering with these pathways, these inhibitors can indirectly modulate the functional state of LOC100041287
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Staurosporine is a potent kinase inhibitor that can disrupt various signaling pathways, potentially influencing the activity of LOC100041287 if it is a kinase substrate. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 inhibits PI3K, a key regulator of signaling pathways, possibly affecting LOC100041287 if it is involved in PI3K-dependent signaling. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 selectively inhibits p38 MAP kinase, potentially affecting the function of LOC100041287 if it is part of the MAPK signaling pathway. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin inhibits mTOR, which can affect protein synthesis and cellular growth, possibly influencing LOC100041287 if it is regulated by mTOR signaling. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is another PI3K inhibitor that can disrupt PI3K-dependent signaling, potentially affecting LOC100041287's involvement in these pathways. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a JNK inhibitor that can modify the JNK signaling pathway, potentially influencing the function of LOC100041287 if it is associated with this pathway. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 selectively inhibits MEK, potentially altering the activity of LOC100041287 if it plays a role in the MAPK/ERK signaling pathway. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Bortezomib inhibits the proteasome, which may affect protein degradation processes involving LOC100041287 if it is a substrate for proteasomal degradation. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dasatinib is a Src family kinase inhibitor, potentially affecting LOC100041287 if it is regulated by Src kinase activity. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $25.00 $117.00 $209.00 | 27 | |
Imatinib inhibits certain tyrosine kinases, which can influence LOC100041287 activity if it is affected by these kinases. | ||||||